Esperion Therapeutics Inc (ESPR) Rating Reiterated by Royal Bank of Canada

Esperion Therapeutics Inc (NASDAQ:ESPR)‘s stock had its “hold” rating reiterated by equities research analysts at Royal Bank of Canada in a research report issued to clients and investors on Monday. They presently have a $45.00 price objective on the biopharmaceutical company’s stock. Royal Bank of Canada’s target price suggests a potential upside of 90.11% from the company’s current price.

A number of other research analysts also recently commented on ESPR. Needham & Company LLC set a $25.00 price target on Esperion Therapeutics and gave the company a “buy” rating in a research note on Saturday, February 4th. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 2nd. Credit Suisse Group AG raised Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday. Finally, Citigroup Inc raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $14.00 to $39.00 in a research note on Tuesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics presently has an average rating of “Buy” and a consensus target price of $29.39.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 74.65% during mid-day trading on Monday, hitting $41.34. 29,887,321 shares of the company were exchanged. The firm has a 50 day moving average of $23.80 and a 200 day moving average of $15.00. The company’s market capitalization is $932.42 million. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $42.59.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.24) by $0.05. During the same quarter last year, the business earned ($0.58) earnings per share. Equities research analysts forecast that Esperion Therapeutics will post ($6.04) earnings per share for the current year.

var userip;Your IP Address: document.write(userip);

Several hedge funds have recently added to or reduced their stakes in the company. Keybank National Association OH purchased a new stake in Esperion Therapeutics during the fourth quarter valued at $159,000. Elkfork Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at $169,000. Advisor Group Inc. boosted its stake in Esperion Therapeutics by 0.6% in the third quarter. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 85 shares during the period. Virginia Retirement Systems ET AL purchased a new stake in Esperion Therapeutics during the third quarter valued at $242,000. Finally, Dimensional Fund Advisors LP boosted its stake in Esperion Therapeutics by 54.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 40,220 shares of the biopharmaceutical company’s stock valued at $504,000 after buying an additional 14,257 shares during the period. Institutional investors own 64.65% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

5 Day Chart for NASDAQ:ESPR

Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million
New York Approves Free College Tuition
New York Approves Free College Tuition
Obamacare Market in Iowa Hit Hard by Aetna
Obamacare Market in Iowa Hit Hard by Aetna


© 2006-2017 Ticker Report. Google+.